CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

MoonLake Immunotherapeutics

MLTX
$1.10BSmall Cap

Next catalyst

Phase 3January 2027

Sonelokimab

Hidradenitis Suppurativa

Get an email about MLTX's next catalysts

Track MoonLake Immunotherapeutics (MLTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 3Next

Sonelokimab Phase 3 Est. Readout (IZAR-2)

January 2027~Sonelokimab600

Estimated primary completion for Sonelokimab trial (NCT06641089) in Arthritis, Psoriatic. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaZUG100 employees
Drug Pipeline

Frequently asked questions

What is in MoonLake Immunotherapeutics's drug pipeline?β†’

CatalystAlert tracks 3 drug candidates in MoonLake Immunotherapeutics's (MLTX) pipeline across Phase 3, Phase 2. Its lead program is Sonelokimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is MoonLake Immunotherapeutics's next FDA catalyst?β†’

MoonLake Immunotherapeutics's (MLTX) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track MLTX biotech catalysts?β†’

Add MLTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MoonLake Immunotherapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply